Literature DB >> 11866593

A rationally designed genotoxin that selectively destroys estrogen receptor-positive breast cancer cells.

Kaushik Mitra1, John C Marquis, Shawn M Hillier, Peter T Rye, Beatriz Zayas, Annie S Lee, John M Essigmann, Robert G Croy.   

Abstract

We describe a novel strategy to increase the selective toxicity of genotoxic compounds. The strategy involves the synthesis of bifunctional molecules capable of forming DNA adducts that have high affinity for specific proteins in target cells. It is proposed that the association of such proteins with damaged sites in DNA can compromise protein function and/or DNA repair resulting in increased toxicity. We describe the synthesis of a bifunctional compound consisting of an aniline mustard linked to the 7alpha position of estradiol. This novel compound can form covalent DNA adducts that have high affinity for the estrogen receptor. Breast cancer cells that express high levels of the estrogen receptor showed increased sensitivity to the cytotoxic effects of the new compound.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11866593      PMCID: PMC4095803          DOI: 10.1021/ja017344p

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  28 in total

Review 1.  Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.

Authors:  L J Lerner; V C Jordan
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

2.  Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links.

Authors:  W E Ross; R A Ewig; K W Kohn
Journal:  Cancer Res       Date:  1978-06       Impact factor: 12.701

3.  New biospecific adsorbents for the purification of estradiol receptor.

Authors:  R Bucourt; M Vignau; V Torelli
Journal:  J Biol Chem       Date:  1978-11-25       Impact factor: 5.157

4.  Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II)

Authors:  J H Toney; B A Donahue; P J Kellett; S L Bruhn; J M Essigmann; S J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

5.  Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor.

Authors:  S M Rink; K J Yarema; M S Solomon; L A Paige; B M Tadayoni-Rebek; J M Essigmann; R G Croy
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

6.  Inhibition of DNA repair in cells treated with a combination of alkylating agents.

Authors:  O S Frankfurt; D Seckinger; E V Sugarbaker
Journal:  Anticancer Res       Date:  1993 Jul-Aug       Impact factor: 2.480

7.  Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin.

Authors:  S J Brown; P J Kellett; S J Lippard
Journal:  Science       Date:  1993-07-30       Impact factor: 47.728

8.  HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.

Authors:  J C Huang; D B Zamble; J T Reardon; S J Lippard; A Sancar
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

9.  Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells.

Authors:  J Hansson; R Lewensohn; U Ringborg; B Nilsson
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701

10.  Alkylation of DNA by the nitrogen mustard bis(2-chloroethyl)methylamine.

Authors:  M R Osborne; D E Wilman; P D Lawley
Journal:  Chem Res Toxicol       Date:  1995-03       Impact factor: 3.739

View more
  16 in total

1.  Design, synthesis, and initial biological evaluation of a steroidal anti-estrogen-doxorubicin bioconjugate for targeting estrogen receptor-positive breast cancer cells.

Authors:  Kinh-Luan Dao; Rupa R Sawant; J Adam Hendricks; Victoria Ronga; Vladimir P Torchilin; Robert N Hanson
Journal:  Bioconjug Chem       Date:  2012-04-04       Impact factor: 4.774

2.  Design, synthesis, and evaluation of estradiol-linked genotoxicants as anti-cancer agents.

Authors:  U Sharma; J C Marquis; A Nicole Dinaut; S M Hillier; B Fedeles; P T Rye; J M Essigmann; R G Croy
Journal:  Bioorg Med Chem Lett       Date:  2004-07-16       Impact factor: 2.823

3.  A lipid-modified estrogen derivative that treats breast cancer independent of estrogen receptor expression through simultaneous induction of autophagy and apoptosis.

Authors:  Sutapa Sinha; Sayantani Roy; Bathula Surendar Reddy; Krishnendu Pal; Godeshala Sudhakar; Seethalakshmi Iyer; Shamit Dutta; Enfeng Wang; Pawan Kumar Vohra; Karnati Rammohan Roy; Pallu Reddanna; Debabrata Mukhopadhyay; Rajkumar Banerjee
Journal:  Mol Cancer Res       Date:  2011-02-02       Impact factor: 5.852

4.  A bifunctional platinum(II) antitumor agent that forms DNA adducts with affinity for the estrogen receptor.

Authors:  Eunsuk Kim; Peter T Rye; John M Essigmann; Robert G Croy
Journal:  J Inorg Biochem       Date:  2008-10-26       Impact factor: 4.155

5.  Probing the topological tolerance of multimeric protein interactions: evaluation of an estrogen/synthetic ligand for FK506 binding protein conjugate.

Authors:  Terry W Moore; Jillian R Gunther; John A Katzenellenbogen
Journal:  Bioconjug Chem       Date:  2010-10-20       Impact factor: 4.774

6.  Synthesis and evaluation of 11β-(4-substituted phenyl) estradiol analogs: transition from estrogen receptor agonists to antagonists.

Authors:  Robert N Hanson; Edward Hua; J Adam Hendricks; David Labaree; Richard B Hochberg
Journal:  Bioorg Med Chem       Date:  2012-05-07       Impact factor: 3.641

7.  Design of a platinum-acridine-endoxifen conjugate targeted at hormone-dependent breast cancer.

Authors:  Song Ding; Xin Qiao; Gregory L Kucera; Ulrich Bierbach
Journal:  Chem Commun (Camb)       Date:  2013-03-25       Impact factor: 6.222

8.  Analysis of protein covalent modification by xenobiotics using a covert oxidatively activated tag: raloxifene proof-of-principle study.

Authors:  Ju Liu; Qian Li; Xiaofeng Yang; Richard B van Breemen; Judy L Bolton; Gregory R J Thatcher
Journal:  Chem Res Toxicol       Date:  2005-09       Impact factor: 3.739

9.  Selective estrogen receptor modulator delivery of quinone warheads to DNA triggering apoptosis in breast cancer cells.

Authors:  Kuan-Wei Peng; Huali Wang; Zhihui Qin; Gihani T Wijewickrama; Meiling Lu; Zhican Wang; Judy L Bolton; Gregory R J Thatcher
Journal:  ACS Chem Biol       Date:  2009-12-18       Impact factor: 5.100

10.  Convergent synthesis of a steroidal antiestrogen-mitomycin C hybrid using "click" chemistry.

Authors:  Robert N Hanson; Edward Hua; David Labaree; Richard B Hochberg; Kyle Proffitt; John M Essigmann; Robert G Croy
Journal:  Org Biomol Chem       Date:  2012-09-25       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.